Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer is a phase 3, randomised interventional study registered as NCT04922853 by West China Hospital, with a registry enrolment figure of 554 participants, started 2021-08-26 and due to reach its primary completion in 2024-10-01. Interventions recorded: Capox chemotherapy. Conditions listed: Rectal Cancer; Neoadjuvant Chemotherapy. Primary outcome: pathological Tumor Regression Grade evaluation. Colorectal eligibility wording from the registry: "Patients diagnosed with low/intermediate risk stage II/III rectal cancer under MRI and transanal ultrasound,defined as: low:T3a-bN0-1M0, EMVI (±), MRF (-) (≥2mm); Middle-high rectal cancer: T3a-cN0-1M0, EMVI (±), MRF (-) (≥2mm); No more than 3 lymph nodes with short diameter over 8mm or highly suspe". Sites: China. No results are recorded here; the registry entry is the source.